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“The past is of no importance. The present is 
of no importance. It is with the future that 
we have to deal…” 
 
Oscar Wilde (1854-1900) 
 
 
 
 
“If it were not for the great variability 
among individuals medicine might as well 
be a science and not an art.“  
 
Sir William Osler (1892) 
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Abstract (Italian version) 
 
Questo progetto di dottorato di ricerca è finalizzato allo studio 
dell'applicazione nella pratica clinica attuale della medicina di comunità, 
di tests farmacogenetici utili sia per la determinazione di polimorfismi 
noti per influenzare la dose iniziale di warfarin nella terapia 
anticoagulante orale, sia per l’analisi dei polimorfismi associati alla 
risposta di farmaci antidepressivi. Gli studi si sono perciò svolti in 
collaborazione con la medicina territoriale, al fuori dei centri di eccellenza 
e le rigorose condizioni in cui di solito vengono eseguiti i trials. In 
quest’ottica, i risultati finora ottenuti, in accordo con la letteratura 
corrente, supportano l'impiego dell’analisi dei polimorfismi per la 
determinazione della corretta dose iniziale di warfarin. Inoltre, il 
polimorfismo del trasportatore della serotonina (5-HTTLPR) è stato 
valutato in relazione alla risposta ai farmaci antidepressivi appartenenti 
alla classe degli inibitori selettivi della ricaptazione della serotonina 
(SSRI), e anche nella medicina di comunità, sia in pazienti oncologici che 
psichiatrici, l’analisi di 5-HTTLPR sembra essere uno strumento utile per 
predire l’esito della risposta al trattamento con SSRI. 
Infine, con lo sviluppo di nuove tecnologie, i costi per l'analisi genetica 
sono diminuiti,e possono essere considerati limitati soprattutto in 
relazione ai vantaggi raggiunti con il loro impiego. In ogni caso, il 
rapporto costo-efficacia dei test farmacogenetici potrebbe essere 
migliorato con lo sviluppo di ulteriori devices che permettano un’analisi 
più veloce ed economica. 
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Abstract (English version) 
 
This PhD project is aimed to the study of the application, in the 
current clinical practice of the community medicine, of pharmacogenetic 
tests known to be associated with the prediction of warfarin dose at the 
initiation of the oral anticoagulant therapy and moreover, the test for the 
analysis of the polymorphism related to the response to the 
antidepressant drugs. The study was carried out in the community care, 
out of the centers of excellence and the strict conditions in which usually 
the trials are performed. From this perspective, the results obtained so 
far, according to the current literature, support the use of the analysis of 
polymorphisms in determining the correct dose of warfarin.  
Furthermore, polymorphism of the serotonin transporter (5-
HTTLPR) has been assessed in relation to response to antidepressant 
drugs belonging to the class of Selective Serotonin Reuptake Inhibitors 
(SSRIs), and also in community medicine, both in oncological and 
psychiatric patients, the analysis of 5-HTTLPR seems to be a useful tool to 
predict the outcome of the response to treatment with SSRIs. Finally, 
Since the development of new technologies, the costs for genetic analysis 
have been decreased, and may be considered limited, particularly in 
relation to the benefits achieved with their use. In any case, the cost-
effectiveness of pharmacogenetic tests could be improved by the 
development of further devices that allow a faster and cheaper analysis. 
  
 
 
 
 
 
 
 
 
Chapter I 
Background 
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1.1 Pharmacogenetics and its application in pharmacology  
 
1.1.1 Introduction 
 
Most patient populations show large inter-individual variability in 
drug response and toxicity. For all major classes of drugs given at 
standard doses, a substantial proportion of patients do not respond, 
respond only partially, or experience adverse drug reactions1 (ADRs) (see 
Fig 1).  
 
 
Figure 1. The potential of pharmacogenetic is to identify patients within 
a population with the same diagnosis, who are genetically predisposed 
either not to respond to therapy or to develop unacceptable toxicity, and 
then to prospectively alter their therapy to avoid treatment that is not 
likely to be optimal. The remaining, now more homogeneous population, 
can then be treated with conventional therapy in which they are not 
genetically predisposed to fail.1 
C h a p t e r  I - B a c k g r o u n d | 3 
 
Drug concentrations in plasma can vary more than 600-fold between two 
individuals of the same weight on the same drug dosage. This variation 
can be of genetic, physiological, pathophysiological, or environmental 
origin, but a drug’s absorption, distribution and metabolism, and 
interactions with its target can be determined by genetic differences.1 
Genetic variation in humans was recognized as an important determinant 
of individual variability of drug response from clinical observations in 
late 1950s.2-4 In these cases, patients with very high or low plasma or 
urinary drug concentrations that correspond to a specific phenotype of a 
drug response were identified, and the biochemical traits leading to the 
variation of drug concentrations were found to be inherited. The 
observation that individual variation of a drug response is often larger 
among members in a population (population variability) than within the 
same person at different times (intrapatient variability) further supports 
inheritance as a major determinant of drug response.5-6 These clinical and 
population-based findings fostered the formation of pharmacogenetic to 
specifically address genetic contribution to individual variability in drug 
therapy.7 The human genome sequence provides a special record of 
human evolution that varies among populations and individuals. 
Sequence variations in drug target proteins, drug-metabolizing enzymes, 
and drug transporters can alter drug efficacy, drug side effects, or both to 
cause variable drug responses in individual patients.8-14 From this 
prospect, the availability of the complete human genome sequence has 
made it possible to analyze the impact of variations of the human genome 
sequence on the pathogenesis of important diseases and the response to 
drug therapy. Moreover, the rapid development of techniques in the area 
of genome analysis has facilitated the identification of pharmacogenetic 
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biomarkers that can provide predictive tools for improved drug response 
and fewer ADR (see Tab. 1). 
 
 
 (Table adapted from Evans WE and Relling MV, Nature 2004) 
 
 
Since their penetrance in the population, and the significant 
functional role, this thesis considered the variations in the genes 
associated with the oral anticoagulant agent warfarin, and those related 
to the pharmacogenetic of SSRIs antidepressant drugs. 
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1.1.2 Warfarin 
 
Warfarin sodium is an anticoagulant drug which acts by inhibiting 
vitamin K-dependent coagulation factors. Chemically, it is a derivative of 
4-hydroxycoumarin with a nonpolar carbon substituent at the 3 position 
(see Fig. 2) which is asymmetrical. The enantiomers differ in 
anticoagulant potency (the S form is more potent), metabolism, 
elimination, and interaction with other drugs. Commercial formulation is 
a racemic mixture of the R- and S-enantiomers. 
 
 
 
Figure 2. Warfarin structure 
(The red circle indicates the chiral centre) 
 
 
Warfarin is indicated for the prophylaxis and/or treatment of venous 
thrombosis and its extension, and pulmonary embolism; for the 
prophylaxis and/or treatment of the thromboembolic complications 
associated with atrial fibrillation and/or cardiac valve replacement and to 
reduce the risk of death, recurrent myocardial infarction, and 
thromboembolic events such as stroke or systemic embolization after 
myocardial infarction. 
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Pharmacological properties 
 
Mechanism of action 
 
Warfarin acts by inhibiting the synthesis of vitamin K dependent 
clotting factors, which include Factors II, VII, IX and X, and the 
anticoagulant proteins C and S. Half-lives of these clotting factors are as 
follows: Factor II - 60 hours, VII - 4 to 6 hours, IX - 24 hours, and X - 48 to 
72 hours. The half-lives of proteins C and S are approximately 8 hours 
and 30 hours, respectively. The resultant in vivo effect is a sequential 
depression of Factor VII, Protein C, Factor IX, Protein S, and Factor X and 
II activities. Vitamin K is an essential cofactor for the post ribosomal 
synthesis of the vitamin K dependent clotting factors. The vitamin 
promotes the biosynthesis of γ-carboxyglutamic acid residues in the 
proteins which are essential for biological activity. Warfarin is thought to 
interfere with clotting factor synthesis by inhibition of the C1 subunit of 
the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby 
reducing the regeneration of vitamin K1 epoxide (see Fig. 3). Therapeutic 
doses of warfarin decrease the total amount of the active form of each 
vitamin K dependent clotting factor made by the liver by approximately 
30% to 50%. An anticoagulation effect generally occurs within 24 hours 
after drug administration. However, peak anticoagulant effect may be 
delayed 72 to 96 hours. The duration of action of a single dose of racemic 
warfarin is 2 to 5 days. The effects of warfarin may become more 
pronounced as effects of daily maintenance doses overlap. 
Anticoagulants have no direct effect on an established thrombus, nor do 
they reverse ischemic tissue damage. However, once a thrombus has 
occurred, the goal of anticoagulant treatment is to prevent further 
extension of the formed clot and prevent secondary thromboembolic 
complications which may result in serious and possibly fatal 
consequences. 
 
 
Figure 
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3. Warfarin’s mechanism of action 
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Metabolism 
 
The elimination is almost entirely by metabolism. Warfarin is 
stereoselectively metabolized by hepatic microsomal enzymes 
(cytochrome P-450) to inactive hydroxylated metabolites (predominant 
route) and by reductases to reduced metabolites (warfarin alcohols). The 
warfarin alcohols have minimal anticoagulant activity. The metabolites 
are principally excreted into the urine; and to a lesser extent into the bile. 
The metabolites of warfarin that have been identified include 
dehydrowarfarin, two diastereoisomer alcohols, 4′-, 6-, 7-, 8- and 10-
hydroxywarfarin. The cytochrome P-450 isozymes involved in the 
metabolism of warfarin include 2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. 2C9 
is likely to be the principal form of human liver P-450 which modulates 
the in vivo anticoagulant activity of warfarin. The warfarin (S)-isoform is 
metabolised predominantly by the CYP2C9 enzyme, which converts the 
drug in the 7-hydroxy and 6-hydroxy inactive metabolites that are 
excreted in the urine.15 
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Pharmacogenetic of warfarin 
 
CYP2C9 
 
The human CYP2C9 gene is located on the chromosome 10 
(10q24.2), is approximately 55 Kb long, contains 9 exons and encodes for a 
60 kDa microsomal protein. More than 50 variants in CYP2C9 have been 
described and, among these, and the most common allele, designated as 
CYP2C9*1, is considered the wild-type genotype. Two single nucleotide 
polymorphisms (SNPs), CGT>TGT in the exon 3, inducing the Arg144Cys 
substitution, and ATT>CTT in the exon 7, encoding for the Ile359Leu 
variant, denoted as CYP2C9*2 andCYP2C9*3 allele, respectively16,17, play 
an important role in warfarin metabolism and are relatively common 
among Caucasian populations.18 The allelic frequencies of CYP2C9*2 and 
CYP2C9*3 diverge considerably among different ethnic groups. In 
Caucasians, the allelic frequencies of CYP2C9*2 and CYP2C9*3 vary 
approximately from 8% to 20% and from 6% to 10%, respectively.19 They 
are less frequent in Asian and African-American populations. Indeed, 
CYP2C9*2 is not present in Asians and only 2–4% of African-Americans 
carry this allele. CYP2C9*3 is present in 1–4% of Chinese, Korean and 
Japanese populations, and in 1–2% of African-Americans.20-23 
 In vitro, CYP2C9*2 and CYP2C9*3 are functionally defective and, as 
compared with the wild-type enzyme, exhibit only 12% and 5% of 
metabolic efficiency, respectively.24-26 The decreasing in catalytic activity 
of the CYP2C9*2 allele can be attributed to its impaired ability to interact 
with the NADPH-CYP450 reductase in the oxidative metabolism 
cascade.28 The enzyme encoded by the CYP2C9*3 allele shows an altered 
affinity for the substrate.20,24 The clinical effects of these polymorphisms 
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are well documented in vivo. Furuya and co-workers were the first to 
report the influence of CYP2C9 polymorphisms on warfarin dose 
requirement in vivo. They reported that patients with the CYP2C9*1/*2 
genotype required, on average, a 20% lower warfarin dose to maintain a 
target INR (international normalized ratio) between 2 and 4 compared to 
the anticoagulated patient population studied. Moreover, 90% of patients 
requiring the lowest warfarin dose were heterozygous for *2.28 Aithal et 
al. demonstrated that the odds ratio for an individual on low-dose 
warfarin having one or more of the variant CYP2C9 alleles as compared 
with the general patient population is 6.21 (95% CI 2.48–15.6). They also 
showed that individuals in the low-dose group were more prone to 
difficulties at the time of induction and were four times more likely to 
develop major bleeding complications than the general clinic group.29 In 
the 2002, Scordo et al. confirmed the association between CYP2C9 
polymorphism and warfarin dose requirement that had, by then, been 
reported by several other studies. However, 30% of the patients with the 
wild-type CYP2C9 genotype were found to require low daily warfarin 
doses, indicating the possibility that other genetic, environmental, 
physiological, and pathological factors were contributing to warfarin 
dose requirement.30 A systematic review and meta-analysis of data 
relating to 2775 patients established that 20% of patients studied carried a 
CYP2C9 variant allele, with *2 at 12.2% (range: 9.7%–15.0%) and *3 at 
7.9% (range: 6.5%–9.7%). Mean reduction in daily warfarin dose for the 
CYP2C9*2 genotype was 0.85 mg/day (0.60– 1.11 mg), a 17% reduction, 
and for CYP2C9*3 it was 1.92 mg/day (1.37–2.47 mg), a 37% reduction. 
For the CYP2C9*2/*3 genotype the reduction in dose was 1.47 mg (1.24–
1.71 mg), a 27% reduction. The relative bleeding risk for CYP2C9*2 was 
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1.91 (1.16–3.17), and for CYP2C9*3 it was 1.77 (1.07–2.91). For either 
variant, the relative risk was 2.26 (1.36-3.75).31 
 
VKORC1 
 
The gene that encodes for the vitamin K epoxide reductase complex 
1 (VKORC1), the target enzyme for warfarin, has been recently 
identified.32,33 VKORC1 gene maps to the short arm of chromosome 16 
and contains three exons coding for an 18-kDa integral membrane 
protein. Several groups have demonstrated a dependence of warfarin 
dose on the polymorphic VKORC1 gene31,34-36 although other factors, 
including non-compliance, accelerated metabolism, and excessive dietary 
vitamin K, may contribute to a resistance phenotype independent of 
VKORC1 status. A number of different SNPs have been identified and 
Rieder and colleagues have created a widely used haplotype grouping 
system including five main haplotypes significantly associated with 
stable warfarin dose, which were segregated into two haplotype groups: 
a low-dose haplotype group (“A”) and a high-dose group (“B”). These 
haplotype groups explain approximately 20% to 25% of the variability in 
stable warfarin dose, and are strongly related to mRNA levels for 
VKORC1, with the high-dose group having higher mRNA levels.37 Two 
VKORC1 SNPs have been proven to be important genetic determinants of 
inter-individual warfarin dose variability and then are commonly 
considered in the study considering the genetic influence of VKORC1 on 
warfarin dose, the G>A substitution in position −1639 (rs9923231) and the 
C>T variation in 1173 (rs9934438).41 The A allele in position −1639 allele is 
associated with the need of lower doses than the G allele. The association 
is such that a homozygous carrier of the A allele requires a warfarin dose 
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approximately 50% of that of an individual that is homozygous for the G 
allele. Similar effects have been ascribed to the VKORC 1173C>T 
polymorphism.39 However, these two SNPs are in pronounced linkage 
disequilibrium and are interchangeably used as tag SNPs for 
differentiation between a low-dose haplotype A (−1639A and 1173T) and 
a high-dose haplotype B (−1639G and 1173C).36 Other SNPs have been 
independently associated with altered warfarin dose requirements, but 
their contribution to the inter-individual variability is small compared to 
the −1639G>A and 1173C>T polymorphisms.40,41 The warfarin 
maintenance dose differs significantly between the three combinations of 
haplotype groups, with a dose of 2.7±0.2 mg/day for group A/A, 4.9±0.2 
mg/day for group A/B, and 6.2±0.3 mg/day for group B/B. Thus, 
VKORC1 haplotypes can be used to stratify patients into low-, 
intermediate-, and high-dose warfarin groups and may explain 
differences in dose requirements among patients. The VKORC1 
haplotype group A is more frequent in Asians (89%), while the haplotype 
group B does in Caucasians (58%).37 All these data are concordant with 
the clinical observation that Asians require lower doses of warfarin than 
their Caucasian counterpart to achieve the same degree of 
anticoagulation and suggest that, in people from a different ethnic 
background, the VKORC1 plays a pivotal role in the modulation of inter-
individual variability of warfarin response.42,43 
In Caucasian and Asian populations, VKORC1 genotype predicts 25% of 
the variability in warfarin dose.44 
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Other genes 
  
In addition to CYP2C9 and VKORC1, there are several other genes 
that may influence variation in warfarin dose and response. The most 
widely replicated of these is a nonsynonymous SNP in CYP4F2 
(rs2108622, V433M).45,46 The inclusion of CYP4F2 variant in the dosing 
models showed an improvement in the overall predictability of warfarin 
dose47-54, however some contradictory reports showing that the 
contribution of this variant to warfarin dose was negligible.55-58 Variants 
in CALU (gene encoding Calumenin) and GGCX (γ-glutamil carboxylase) 
have been shown to affect warfarin dose in some but not all 
populations.59-60  
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Influence of the genetic polymorphisms on warfarin dose 
 
Warfarin metabolism is influenced by a number of pathological, 
physiological, and environmental factors. Although it had long been 
recognized that warfarin dose requirement falls with increasing age and 
liver size, and that body size is an indirect marker of this association61, 
induction regimens have remained crude, and overanticoagulation 
during the initiation phase is common, especially in older patients.62 The 
clinical potential for recognition of genetic polymorphisms that account 
for extremes in phenotypic response in advance of therapy, and tailoring 
dosage appropriately, has been underpinned by studies showing a 
relationship between genotype and risk of adverse drug effects. The 
clinical importance of the association between CYP2C9 genotypes and 
bleeding was confirmed in a retrospective cohort study that established 
CYP2C9 genotype as an independent predictor of a first bleeding event 
during the initiation phase of warfarin therapy (HR 3.94; 95% CI 1.29–
12.06). Patients carrying CYP2C9 variant alleles had a higher rate of 
above-range INR values, took longer to reach stable dosing, and had a 
higher risk of serious and life-threatening bleeding events than patients 
with the wild-type allele.63 Similar results were noted in a study of 
warfarin-treated patients where CYP2C9*2 or *3 compound heterozygous 
and homozygous had low warfarin requirements and increased rates of 
excessive (INR>6.0) anticoagulation and bleeding compared with wild-
type patients.64 In a retrospective cohort analysis of 172 patients, patients 
with CYP2C9 variants, compared to those without, achieved stable dose 
48% later ( p < 0.01), spent a higher proportion of time above range in the 
first month of therapy (14% versus 25%, p = 0.07), and had an odds ratio 
of 4.15 for an INR>5. In contrast, although patients homozygous for the 
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VKORC1 low-dose haplotype (AA) had an odds ratio of 4.47 for an 
INR>5, no other influence was noted on outcomes measured.65 The 
recognition that genotype affects the likelihood of serious and life-
threatening bleeding66 highlighted the inadequacy of current dosing 
regimes. The quantification of the impact of genetics on warfarin dose 
requirement led to the concept that information on genotype, or any other 
factor that influences the interindividual variability in dose requirement, 
could be used toward a more individualized approach to warfarin 
therapy. Several studies have quantified the contribution of various 
genetic, clinical, and environmental factors to warfarin dose requirement 
based on retrospective analysis of data obtained from patients on 
maintenance therapy. In a North American population, the extent of the 
influence of CYP2C9*2 and *3, age, and body surface area (BSA) on 
maintenance warfarin dose was quantified at 19% per ∗2 allele, 30% per 
*3 allele, 8% per decade of age, and 13% per standard deviation decrease 
in BSA, with dose being 29% lower in patients who took amiodarone (a 
potent inhibitor of warfarin metabolism commonly used in elderly 
patients with cardiac arrhythmia), 12% lower in patients who took 
simvastatin, 21% lower in patients whose target INR was 2.5 rather than 
3.0, and 11% lower in whites compared to African American patients. 
Regression analysis of data that included these factors and sex (which 
was of borderline significance) explained 39%of the variance in warfarin 
maintenance dose.67 In 453 Caucasian patients the CYP2C9 genotype 
frequencies for *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3 were 65.1%, 
19.0%, 12.1%, 1.6%, 1.8%, and 0.4%, respectively. Mean maintenance 
doses for these genotypes were 36.5, 29.1, 23.5, 28.0, 18.1, and 5.5 
mg/week, respectively. In univariate analysis, genotype alone accounted 
for 19.8% of the variability in maintenance dose. Age, BSA, and male sex 
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accounted for 14.6%, 7.5%, and 4.7%, respectively, while cardiac valve 
replacement as the indication for warfarin accounted for 5.4% of the 
variability. Collectively, these factors accounted for 33.7% of the 
variability in dose requirement according to multiple regression 
analysis.68 The discovery of the contribution of the VKORC1 genotype to 
warfarin dose requirement allowed further assessment of the importance 
of genetic factors. Sconce et al. demonstrated that variables of age, height, 
and CYP2C9 and VKORC1 genotype altogether explained 55% of the 
inter-individual variability in dose requirement in a cohort of stable 
patients.69 A dosing equation based on regression analysis of data was 
subsequently developed. The validity of the dosing equation in 
predicting stable maintenance dose was confirmed in a second cohort of 
patients on warfarin therapy. In a prospective study of outpatients in the 
United States, genotype was the dominant predictor of warfarin dose, 
explaining 33% of dose variance compared to 12% for age, weight, and 
sex. Warfarin dose requirement was reduced by 18%–72% in patients 
with a single or double CYP2C9 variant allele and by 65% in those with a 
VKORC1 variant. Genetics-based modeling explained almost half of the 
variability in dose requirement.70 Caldwell et al. noted that CYP2C9 and 
VKORC1 along with clinical factors of age, sex, BSA, and the presence or 
absence of prosthetic heart valves or diabetes explained 50% of the 
variability of stable warfarin maintenance dose, whereas, in contrast, 
GGCX, factor VII, and APOE polymorphisms contributed little to the 
variability.71 In a Swedish study, during initiation of therapy, 
homozygosity for CYP2C9 and VKORC1 variant alleles increased the risk 
of overanticoagulation; hazard ratios were 21.84 (95% CI 9.46–50.42) and 
4.56 (95% CI 2.85–7.30), respectively.72 One of eight patients with 
CYP2C9*3/*3 genotype (12.5%) experienced severe bleeding during the 
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first month compared with 0.27% of other genotypes. A multiple 
regression model using the predictors CYP2C9, VKORC1, age, sex, and 
drug interactions explained 59% of the variance in warfarin dose 
requirement. When this was applied to an independent sample of 181 
Swedish individuals, it explained 53% of dose variance. In a cohort of 
1015 patients, the independent predictors of maintenance dose were 
VKORC1 polymorphism −1639/3673G>A (−28% per allele), BSA (+11% 
per 0.25 m), CYP2C9*3 (−33% per allele), CYP2C9*2 (−19% per allele), age 
(−7% per decade), target INR (+11% per 0.5 unit increases), amiodarone 
use (−22%), smoker status (+10%), race (−9%), and current thrombosis 
(+7%). The above covariates explained 53%–54% of the variability in 
warfarin dose requirement. For comparison, a regression analysis 
including nongenetic factors explained only 17%–22% of the dose 
variability.73 In recognition of the interethnic difference in allele and 
haplotype frequencies of genes for CYP2C9 and VKORC1, Wu et al. 
developed algorithms that included Caucasian, African American, Asian, 
and Hispanic ethnicity, which all produced a similar degree of 
correlation74; the exclusion of rare genotypes that are more associated 
with certain ethnicities improved the model to a minor extent. A 
genotyping approach based on SNPs in CYP2C9*9, and VKORC1 CC and 
TC genotypes at position 381, in combination with age and weight, 
accounted for 60.2% of the variability in warfarin dose requirement in an 
Asian population. A model based on these, when validated in a separate 
cohort, showed a mean underestimation in dose of 0.23 ± 1.21 mg/day.75 
The future clinical utility of pharmacogenetics will require the 
development of a dosing equation that incorporates information on 
genetic as well as clinical and patient factors. Although a number of such 
equations have been proposed, most are highly geographically confined, 
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and none was developed from robust data in a population containing 
patients of Asian, European, and African descent. A dosing equation 
derived from a large, geographically and ethnically diverse population 
would be a step toward global clinical utility of a pharmacogenetics-
guided dosing regimen. Recently, the International Warfarin 
Pharmacogenetics Consortium (IWPC), made up of researchers from 21 
centers in nine countries on four continents (Asia, Europe, North 
America, and South America), developed an algorithm for estimating 
warfarin dose based on both clinical and genetic data from a broad 
patient population base. Data belonging to 4043 patients, with a target 
INR of 2–3, were used to create a dosing algorithm that was based on 
clinical variables only and an algorithm in which genetic information was 
added to the clinical variables. The accuracy of dose prediction by the 
algorithms was assessed using a validation cohort of 1009 patients. In the 
validation cohort, the pharmacogenetic algorithm accurately identified 
larger proportions of patients who required low or high doses of warfarin 
(weekly totals of 21 mg or less, or 49 mg or more) to achieve the target 
INR than did the clinical algorithm (49.4% versus 33.3%, p < 0.001, among 
patients requiring 21 mg per week or less; and 24.8% versus 7.2%, 
p<0.001, among those requiring at least 49 mg per week). The greatest 
benefits were observed in these low- and high-dose patients, who totaled 
46.2% of the population.76 These are the patients in whom standard 
dosing regimens are most likely to produce underdosing or overdosing of 
warfarin with adverse clinical consequences.  
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1.1.3 Antidepressant Selective Serotonin Reuptake Inhibitors 
(SSRIs)  
 
Depressive disorders constitute a major public health issue and the 
World Health Organization (WHO) has estimated that it is the fourth 
major cause of disability worldwide, and may become second only to 
cardiovascular diseases in the next two decades, thus contributing 
heavily to the global burden of diseases in man, according to Murray and 
Lopez77, who conducted a study for the WHO. Even though 
antidepressant drugs (AD) have successfully been used to treat 
depressive disorders, there is still substantial need for improvement. 
Response to antidepressant therapy is often incomplete with 
approximately 30–40% not responding at all to the first AD given and 
about 60–70% not achieving remission.78 Moreover, AD pharmacotherapy 
is characterized by a delayed time of onset of the clinical improvement 
and by a variety of adverse effects. Such shortcomings of AD medication 
not only lead to personal suffering in both individuals and their families, 
but also impose considerable costs on society.  
The first class of antidepressant drugs developed was the tricyclic 
antidepressants (TCAs). The TCAs were the result of an unsuccessful 
attempt to improve on the antipsychotic effectiveness of phenothiazines 
(medication used in the treatment of schizophrenia). Molecular 
modifications of phenothiazines led to synthesis of imipramine, the first 
clinically useful tricyclic antidepressant. The Selective Serotonin 
Reuptake Inhibitors were developed in response to the need for better 
tolerated, safer antidepressants than the TCAs, but no less effective for 
the symptoms of depression. The first SSRI, fluoxetine, was released in 
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1987. Each of the SSRIs was the product of a development strategy in 
which the goal was to produce a drug capable of inhibiting the reuptake 
of serotonin, but without affecting the various other neuroreceptors (i.e., 
histamine, acetylcholine, and alpha1-adrenergic receptors), affected by 
the TCAs.  
The development of the SSRIs, with their selective mode of action, has 
resulted in a class of antidepressant drugs possessing an improved side-
effect profile, while retaining good clinical efficacy. The fact that SSRIs 
were designed to avoid affecting other neuroreceptors explains many of 
the pharmacological differences between the SSRIs and the TCAs and 
explains the similarities among the SSRIs. The benefits of SSRIs include 
therapeutic effectiveness, a wide therapeutic index, good tolerability, and 
less toxicity in overdose situations. Moreover, SSRIs induce significantly 
less anticholinergic, antihistaminergic and cardiotoxic side-effects than 
TCAs.79 Despite their low adverse effects, SSRIs have been characterized 
by some side actions including nausea, weight gain and sexual 
dysfunction, such as decreased sexual desire, erectile difficulties and 
delayed ejaculation, which is one of the most frequent and persistent SSRI 
adverse effect.80,81 Furthermore, SSRIs have been associated to the 
serotonin syndrome, characterized by changes in autonomic, neuromotor, 
and cognitive-behavioral function triggered by increased serotonergic 
stimulation. 
In addition, SSRI increased the risk compared to placebo of suicidal 
thinking and behavior (suicidality) in children, adolescents, and young 
adults in short-term studies of major depressive disorder (MDD) and 
other psychiatric disorders. Anyone considering the use of SSRI 
antidepressant in a child, adolescent, or young adult must balance this 
risk with the clinical need. Short-term studies did not show an increase in 
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the risk of suicidality with antidepressants compared to placebo in adults 
beyond age 24; there was a reduction in risk with antidepressants 
compared to placebo in adults aged 65 and older. Depression and certain 
other psychiatric disorders are themselves associated with increases in 
the risk of suicide. Patients of all ages who are started on antidepressant 
therapy should be monitored appropriately and observed closely for 
clinical worsening, suicidality, or unusual changes in behavior. Families 
and caregivers should be advised of the need for close observation and 
communication with the prescriber.82  
Anyway, nowadays the SSRIs are considered the mainstay treatment for 
depressive and anxiety disorders due to the therapeutic effectiveness, a 
wide therapeutic index, good tolerability, and less toxicity in overdose 
situations. Six medications (fluoxetine, paroxetine, sertraline, 
fluvoxamine, citalopram, and escitalopram) are currently available in the 
SSRI and five of them (excluding fluvoxamine) are used as first-line drug 
therapy for major depression. They share the same mechanisms of action 
but differ in severity of adverse effects and drug interactions.83 
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Figure 4. Chemical Structure of the most common SSRIs. 
A. Sertraline; B. Fluoxerine; C. Paroxetine; D. Fluvoxamine;  
E. Citalopram; F. Escitalopram 
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Pharmacological properties 
 
Mechanism of action 
 
As their name implies, the SSRIs selectively block serotonin (5HT) 
reuptake. This occurs through inhibitory actions on the Na+/K+ 
adenosine triphosphatase-dependent carrier on presynaptic neurons (see 
Fig. 5). Among the six available SSRIs, citalopram, escitalopram and 
paroxetine are the most potent blockers of 5HT reuptake. Some SSRIs 
have additional antagonist effects on neurotransmitter receptors. For 
example, paroxetine and citalopram have moderate anticholinergic effects 
and sertraline blocks presynaptic dopamine receptors. Escitalopram is a 
stereoisomer of citalopram and has been shown to exert actions at both 
the primary binding sites for the serotonin transporter, and also on 
secondary allosteric binding sites, a property not shared by other SSRIs.84 
There is also evidence from Position Emission Tomography (PET) using a 
ligand for the serotonin transporter, that 80% or greater occupancy of the 
transporter occurs with citalopram, paroxetine, and sertraline at standard 
doses, and no additional binding occurs at higher doses.85 These ﬁndings 
are based on a small sample of depressed patients, and the SSRIs were 
not examined across a wide range of doses. The SSRIs, like their 
predecessors the TCAs, inhibit neurotransmitter reuptake almost 
immediately, but often take 2–3 weeks to exert clinically meaningful 
beneﬁt. This has been linked to down regulation of the 5HT1A terminal 
autoreceptors. In addition, SSRIs, like other antidepressants, stimulate 
neurogenesis, particularly in the CA3 layer of the hippocampus after 2–3 
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weeks of exposure. Animal models of depression using stress paradigms 
show suppression of neurogenesis which is reversed by antidepressants.86  
 
 
Figure 5. SSRIs antidepressant drugs’ 
mechanism of action 
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Metabolism 
 
The SSRIs are generally well absorbed and not affected by food 
administration, with the exception of sertraline, where food can increase 
the plasmatic levels of the drug. They are metabolized by hepatic 
microsomal enzyme that are part of the cytochrome P450 system, 
particularly the CYP2D6 isoenzyme, although the 2C9, 2C19 and 3A4 
isoenzymes are also substrates for several SSRIs (see Tab. 2).87 It is 
important to note that certain SSRIs inhibit their own clearance through 
the inhibition of their metabolizing enzyme, resulting in elevated plasma 
levels and increased side effects. Both ﬂuoxetine and paroxetine are 
strong inhibitors of the CYP2D6 enzyme, and ﬂuvoxamine is a potent 
inhibitor of CYP1A2, CYP3A4, and CYP2C19. Therefore, caution should 
be exercised when combining these drugs with other medications that are 
metabolized through any of these enzymes. The half-life of SSRIs ranges 
from about 15h (ﬂuvoxamine) to over 60h (ﬂuoxetine), with other agents 
in the 30’-6 h range. This means that in all cases, SSRIs can be prescribed 
at least once daily and in the case of ﬂuoxetine, the drug remains capable 
of causing drug-drug interactions 2-3 weeks after the last dose. 
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Pharmacogenetic of SSRI
 
Serotonin transporter linked polymorphic region (5
 
The human serotonin transporter (
HT) neurotransmission in the brain by removing it from the intercellular 
cleft. It is a target of primary interest in the pharmacogenetics of 
antidepressants because it is the principal site of action of m
antidepressant drugs (e
identified and cloned a single gene encoding the human SERT, named 
SLC6A4, localized to chromosome 17q11.1
and consists of 14 exons
 
 
 
Figure 6. The short (“s”) 5
(SLC6A4) produces significantly less 5
indicated by the green arrow, than the long (“l”) variant (red), leading t
higher concentrations of serotonin in the synaptic cleft.
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In the 1996, Heils reported a polymorphism in the transcriptional 
control region upstream of the 5-HTT coding sequence.90 The 
polymorphism is located approximately 1 kb upstream of the 
transcription initiation site and consist in a 44bp insertion/ deletion 
involving 2 units in a sequence of 16 repeated elements which lead to a 
significantly less production of 5-HTT mRNA and consequently less 
protein (see Fig. 6, panel B). The presence of different alleles could affect 
5-HTT expression: the long (“l”) 5-HTTLPR allele has twice the 5-HTT 
expression in the basal state than the short (“s”) allele. It has been 
consistently reported that this functional variation influences the 
antidepressant effect of different classes of antidepressant drugs. 
Moreover, a growing body of evidence links 5-HTTLPR genotypes to a 
variety of psychiatric disorders with affective symptomatology (e.g., 
depression, bipolar disorder, anxiety disorders, eating disorders, 
substance abuse) and to pathological behaviors and personality traits 
related to anxiety, impulsivity and stress.91 A recent meta-analysis92 
confirmed the role of 5-HTTLPR in antidepressant response, showing that 
patients homozygous for the short allele have a selective and slower 
improvement of depressive “core” and somatic anxiety symptoms.93 The 
short/long genotype was recently found to be associated with an odds 
ratio (OR) of 2.37 concerning adverse effects during treatment with SSRIs 
(dermatologic reactions, weight change and fatigue above all), and the 
homozygous short genotype showed an OR of 1.77.94 These findings are 
generally well replicated in studies involving white populations,95-107 
although opposite or inconsistent findings have also been reported.108-112 
On the other hand, studies involving Asian populations usually report 
conflicting results: some studies reported that the short 5-HTTLPR allele 
was associated with better outcomes113-116, some found no effect of 5-
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HTTLPR genotype on treatment efficacy117-119 and some reported that the 
long 5-HTTLPR allele was associated with better outcomes.120-125 
Interestingly, Lotrich and colleagues126 recently reported that paroxetine 
blood concentration was positively associated with Hamilton Rating 
Scale for depression (HAM-D) response in a sample of elderly patients, 
but this association was found to be significant only in carriers of the 
short allele. In contrast, when augmentation strategies have been 
investigated, the short allele has been associated with a better response in 
patients prescribed pindolol or lithium.127,128 This finding may be difficult 
to explain, and to make this challenge even more complex it has been 
reported that women are more sensitive to mood imbalances after 
tryptophan depletion if they are homozygous for the short or long allele, 
with heterozygotes having the most protective genotype.129 Finally, the 
adverse events occurring in newborns of mothers treated with SSRIs had 
a mixed association with genotype, with those with the heterozygous 
long genotype being at higher risk of respiratory distress and those with 
the homozygous short genotype being at higher risk for neuromotor 
symptoms.130 Giraldi and colleagues analyzed the pharmacotherapy of 
SSRIs in relation to the 5-HTTLPR polymorphism in groups of cancer 
patients in their terminal phase of illness, and in particular the different 
response to sertraline, and citalopram.131,132 After two weeks of treatment 
with sertraline, the scores of anxiety of the Hospital Anxiety and 
Depression Scale (HADS), hopelessness-helplessness and anxious 
preoccupation of the Mini-Mental Adjustment to Cancer (Mini-MAC) 
were significantly reduced only in patients homozygous for the “l” allele 
for which there has been also a significant increase in fighting spirit 
scores (Mini-MAC).131 In the cohort of patients treated with citalopram, 
there was a statistically significant reduction of depression scores (HADS) 
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only in patients homozygous for “l” allele, and an increase of fatalism in 
patients with at least one “s” allele.132 
Regarding the inconsistent findings between white and nonwhite 
populations, it must be remembered that, compared with Western 
populations, carrying the long allele is much less frequent in Asian 
populations: inconsistent results found in Asian populations could be 
influenced by this event, and further studies with larger samples are 
needed. Moreover, relevant stratification factors may be strictly genetic: 
in 2005 Hu and colleagues133 reported that only carriers of the A allele at 
the A>G SNP within the long allele of the 5-HTTLPR insertion 
polymorphism yielded high mRNA levels, whereas carriers of the G 
allele were similar to carriers of the low-expressing short allele. This 
finding could partially explain the inconsistent evidence throughout the 
studies, and it mandates a reconsideration of all the investigations 
published before the identification of this mutation. A study by Hu and 
colleagues109 reported that the low expression alleles (short allele and G 
variant within the long allele) were one of the strongest risk factors 
associated with adverse effects from antidepressants. Finally, a genetic 
oriented pretreatment test based on 5-HTTLPR has been found to be 
associated with a better clinical outcome.134  
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1.2 Application of pharmacogenetic in medical practice 
 
Due to technological advances and large-scale DNA sequencing 
projects, pharmacogenetics research has made tremendous progress in 
recent years, with the identiﬁcation of numerous inherited variants that 
inﬂuence drug response.135 As a result, many drug labels have been 
updated with information about the relevance of pharmacogenetic 
biomarkers (see Tab. 3).  
 
Drug Marker Test 
Abacavir HLA-B*5701 Required 
Carbamazepine HLA-B*1502 Required (HAN Chinese) 
Maraviroc CCR5 Required 
Niotinib UGT1A1 Required 
Rasburicase G6PD Required 
Azathioprine TPMT Recommended 
Irinotecan UGT1A1 Recommended 
Warfarin CYP2C9/VKORC1 Recommended 
Atomoxetine CYP2D6 Information only 
Atorvastatin LDL receptor Information only 
Caecitabine DPD Information only 
Capecitabine DPD Information only 
Celecoxib CYP2C9 Information only 
Clopidogrel CYP2C19 Information only 
Codeine CYP2D6 Information only 
Fluoxetine CYP2D6 Information only 
Isoniazide NAT Information only 
Primaquine G6PD Information only 
Tamoxifene CYP2D6/CYP2C19 Information only 
Voriconazole CYP2C19 Information only 
 
Table 3. FDA valid genomic biomarkers. CYP2D6-C9-C19, Cytochrome P-450 
(isoenzyme D6, C9, C19); CCR5, Chemokine C-C motif receptor; DPD, dihydropyrimidine 
dehydrogenase; G6PD, glucose-6-phosphate dehydrogenase; NAT, N-acetyltransferase; 
TPMT, thiopurine methyltransferase; UGT1A1, glucuronosyl transferase 1 family 
polypeptide 1; VKORC1, vitamin K epoxide reductase complex 1. 
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Moreover, in the field of oncology, genetic alterations are often 
characteristic for a specific tumor type and allow a molecular 
characterization of tumors that can provide information regarding 
disease prognosis, treatment response or new targets for drug 
development135 (see Tab. 4).  
 
Drug Marker Test 
Anastrozole ER Required 
Busulfan Ph1 chromosome Required 
Cetuximab EGFR/KRAS Required 
Dasatinib Ph1 chromosome Required 
Exemestane ER Required 
Lapatinib HER2 Required 
Letrozole ER Required 
Panitumumab EGFR/KRAS Required 
Tamoxifene ER Required 
Transtuzumab HER2 Required 
Imatinib c-Kit expression Required 
Tretinoin PML/RAR  Recommended 
 
Table 4. FDA valid genomic biomarkers. EGFR, epidermal growth 
factor receptor; ER, estrogen receptor; HER-2, human epidermal growth factor 
receptor 2; Phl, Philadelphia chromosome; PML/RAR, promyelocytic 
leukaemia-retinoi acid receptor. 
 
 
However, the introduction of pharmacogenetic testing into clinical 
practice has been relatively slow and there are few pharmacogenetic tests 
being carried out in the clinic.136-138 Many reasons have been cited for the 
lack of translation of pharmacogenetic into clinical practice, including the 
lack of awareness about the utility, the scarcity of trials proving the utility 
and cost-effectiveness, the lack of clinical testing services, the lack of 
incentives for diagnostic companies to invest in the development and 
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licensing of tests, the unclear regulatory framework and concerns 
regarding costs and the reimbursement system.137-142 
 
Pharmacoeconomic issue 
 
As previously mentioned, the existence of finite healthcare budgets 
drives the need to consider the opportunity cost of decisions about which 
healthcare interventions to use. Then, there is a need to demonstrate that 
pharmacogenomic interventions offer added value, in terms of the 
relative costs and benefits, compared with current practice. Cost 
effectiveness analysis is the most commonly used method of economic 
evaluation.143 Another factor to consider with respect to the clinical utility 
and cost-effectiveness of pharmacogenetic testing is the actual cost of 
obtaining genetic information. These costs have been decreasing at a 
stunning rate. Only 10 years ago, sequencing of the first complete human 
genome cost over $3 billion and took years to accomplish. Today, the 
same can be obtained in less than a week for less than $20000. A few 
years from now, sequencing a human genome is estimated to cost only 
$1000. Already, a complete human genome can be sequenced for a few 
thousand dollars, a cost that is likely to drop further.144 Cost-effectiveness 
studies may thus lose some of their relevance in the near future with the 
decreasing costs of genetic testing. Furthermore, the increasing 
availability of direct-to-consumer genetic tests enables patients to obtain 
information about their genetic background without consulting their 
physician. This information, once obtained, could be used to optimize 
therapeutic decisions, irrespective of the evidence regarding cost-
effectiveness of pharmacogenetic testing. However, to put this 
information to optimal use, physicians should be able to rely on 
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rigorously created evidence-based CPGs that inform health professionals 
about the relevance of a given genotype in a specific clinical context. 
Without such guidelines, physicians are left with the information 
provided by genotyping companies, in which the evidence on which a 
specific recommendation is based may not always be clear.144 
 
Educational aspects 
 
Clinicians tend to ignore the large amount of new pharmacogenetic 
information and view it as an additional burden and complication of the 
complex process of therapeutic decision-making. This appears to be 
largely due to the lack of education on the science and potential of 
genomics by all parties involved in the medical application of this 
technology.144 This is a major obstacle that has hampered the widespread 
clinical application of PGx. Education in genetics at the undergraduate, 
postgraduate, and continuing medical education levels has trailed behind 
the enormous scientific and technical advances in the field.145 In addition 
to clinicians, this lack of education involves all stakeholders, including: a) 
other healthcare professionals (including researchers); b) patients and 
concerned individuals; c) media journalists, who often transmit incorrect 
information due to their lack of knowledge; d) government-employed 
regulators and politicians; e) hospital administrators; and f) health 
insurance executives and decision-makers. The latter are a very important 
group, since they are the ones who will decide to include 
pharmacogenetic tests in their coverage. A report issued in 2002 by the 
Consortium on Pharmacogenetics in the UK stated that: ‘‘Perhaps the 
greatest single factor affecting the penetration of pharmacogenomics into 
clinical practice and the pace at which it will occur will be the knowledge 
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and acceptance of physicians. Studies indicate that many physicians lack 
basic knowledge of genetics and also frequently fail to take into account 
available information about drugs’’.146 This urgent need was pinpointed 
by the participants of a recent Pharmacogenomics Education Forum of 
the International Society of Pharmacogenomics (ISP), who issued a set of 
recommendations and a Call for Action addressed to Medical, 
Pharmaceutical and Health Schools Deans of Education.147 This document 
urges Deans of Education to incorporate PGx in the core teaching 
curricula of pharmacology without further delay. This step is vital for 
ensuring rapid and successful implementation of personalized medicine 
into medical practice, in pace with the emergence of the latest genomic 
diagnostics tools, and for the benefit of society at large.144 
 
Need for prospective clinical studies 
 
Numerous investigators and other specialists in the field have 
called for prospective clinical studies.148-152 This is connected to the need 
for incentives for the pharmaceutical and the diagnostics industry to 
develop genotyping tools and validate them in the clinical setting via 
clinical studies. However, it has been pointed out that – unless co-
developing a diagnostic to accompany a pharmacogenetic-based drug –
pharmaceutical companies have few incentives to sponsor randomized 
controlled clinical trials of pharmacogenetic-based diagnostics.149 On the 
other hand, the diagnostics industry has great interest in developing new 
pharmacogenetic-based diagnostic tests, but often has insufficient 
resources to sponsor major clinical trials and is not accustomed to testing 
the value of its products using randomized clinical research. Overall, it 
appears that governments should act soon. A thorough analysis of the 
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types of studies required and related problems has recently been 
published, to which the interested reader is referred.149 As stated by 
Gardiner and Begg: “In addition to clinical studies, formal 
pharmacoeconomic studies need to be performed whenever a strong 
evidence-based case is made for pharmacogenetic testing. This is valuable 
from a population perspective when there are limited funds available for 
health care expenditure. However, it is also recognized that the business 
model may intervene, with aggressive marketing, e.g., of genetic tests 
encouraging clinical uptake before the evidence supports use of the test. 
From a ‘‘best evidence’’ perspective, it would be useful for 
pharmacoeconomists to define standards for conducting such studies that 
are both feasible and readily comprehensible”.150 Furthermore, the 
advancement of clinical pharmacogenetic creates an urgent need for the 
establishment of a solid and clearly defined regulatory framework.  
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1.3 Application of nanotechnology in medical practice 
 
Nanotechnology is the creation and utilization of materials, 
devices, and systems through the control of matter on the nanometer 
scale, i.e., at the level of atoms, molecules, and supramolecular 
structures.153 Applications of nanotechnology in the screening, diagnosis, 
and treatment of disease are collectively referred as ‘nanomedicine’. Key 
issues of nanomedicine include miniaturization of devices, novel 
nanosized materials, chip-based technologies, imaging techniques, drug 
delivery, new analytical tools that could quickly lead to a better 
understanding of initiation and progression of disease as well as to the 
personalization of drug’s therapy.154 A handful of nanomaterials are 
being studied in clinical trials or have already been approved by the FDA 
for use in humans (see Fig. 7), and many proof-of concept studies of 
nanomaterials in cell-culture and small-animal models for medical 
applications are under way.155 
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Figure 7. Nanomaterial in clinical trial or FDA-approved 
 
Many of these nanoproducts are designed to target tumors in vivo and 
are intended for use either as drug carriers for therapeutic applications or 
as contrast agents for diagnostic imaging. Furthermore, application of 
nanomaterials is as a label for measuring molecules of interest in biologic 
samples. Nanomaterials are used to either simplify the readout or 
amplify the detection threshold of the diagnostic device.155 Important 
nanotechnological applications for personalized medicine are now 
considered for the development of targeted drug formulations that 
achieve maximum efficacy and optimal safety profiles. For example, 
through conjugation of nanovehicles with an antibody, the guided 
accumulation of the carrying drug in its target antigen located in diseased 
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specific tissue (e.g., cancer) can be directed efficiently.156,157 Furthermore, 
such therapeutic advantages of nanovehicles are also used for imaging 
applications and theranostic approaches, i.e., for systems and strategies in 
which both disease diagnosis and therapy are combined to benefit 
personalized medicine.158 At the same time, specific nanomaterials, 
including nanotubes, dendrimers, liposomes, and quantum dots, are 
being developed as molecular diagnostic probes to target in vivo specific 
tissues or cells, thus implementing imaging techniques and improving 
clinical outcomes.159 
 
Nanoengineered devices 
 
Particle-based systems for drug delivery are limited in a large part 
by the amount of drug that can be loaded on a single particle and, 
although there are several so-called multifunctional particles, their ability 
to control drug release is based on a single actuation such as dissolution 
of the particle. There is also a growing need for more intelligent systems 
that can carry a large payload of active molecules and that can release 
specific amounts in response to pulsatile stimuli over a longer period of 
time. Although such systems are larger in overall size than nanoparticles, 
the fact that nanoscale architecture is used to achieve some of the desired 
properties makes such systems fall into the general class of 
nanotechnology. 160 Also in this class of nanotechnology are devices that 
use nanoscale architecture to confer certain desirable surface 
characteristics. Such nanofabricated devices may be prepared either by a 
bottom-up approach, that is, by assembling single molecules into a 
nanostructure, or by a top-down approach, that is, etching away parts of 
a macromaterial to yield the desired nanoarchitecture. Such surface 
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characteristics can influence the adhesion of bacteria and subsequent 
biofilm formation161 or may influence the adhesion of surrounding cells in 
the case of tissue implants or tissue engineering scaffolds.162,163 
 
Biosensors 
 
There is currently much interest in miniaturizing diagnostic devices 
to improve the portability of such systems and also to reduce the cost of 
such devices. Portable systems capable of providing accurate estimates of 
traditional blood parameters and antigen levels with a single drop of 
blood represent just one potential arena in which a small-scale sensor 
may find application.160 Such ‘biosensor’-based devices would be a major 
advance in medical technology for use in remote locations with limited 
access to medical laboratories in both civilian and military situations. 
Toward this end, nanofabrication methods are currently being employed 
to design devices that are capable of serving as highly sensitive 
biosensors both in vitro and in vivo.160 Although this technology is still 
not as advanced in its clinical application as the particulate systems, it 
nevertheless holds much promise for the future. The current challenges in 
the development of such systems are associated with detection 
sensitivity. Several different approaches are being explored that include 
novel detection modalities or innovative use of biomolecules. In general, 
biosensors consist of a substrate material to which capture molecules are 
attached. The capture molecules are usually proteins or DNA molecules. 
Once a biomarker is captured, it must then produce a directly detectable 
change in the physical properties of the device or might have to be subject 
to some development process to visualize the capture. Electrochemical 
detection appears to be the most common means of detecting such 
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changes. The simplest approach to such a device is the immobilization of 
a capture molecule such as a protein on the surface of an electrode. 
Biomarker binding to the capture protein produces a detectable change in 
the electrochemical signal measured at the electrode. This approach is, 
however, subject to signal loss due to protein inactivation by the surface 
of the electrode.160 Nanotechnology-based approaches have been used to 
prevent surface–protein interaction-induced denaturing of the protein 
and improve sensor performance. For example, DNA dendrimers have 
been used to improve sensor performance in such a device.164 Limits of 
detection were improved by three orders of magnitude over a device 
without the DNA dendrimer interface in detecting salivary protein and 
mRNA markers.164 A similar approach has been applied to a glucose 
sensor using gold nanorods to immobilize glucose oxidase on cellulose 
acetate film165 and for DNA detection using polyaniline nanofibers and 
carbon nanotubes.166 As an alternative to electrochemical detection 
methods, surface plasmon resonance appears to be promising and has 
recently been reported to be sensitive enough for label-free single 
molecule detection.167,168 Also of note is the use of nanostructured devices 
to capture whole cells. A three-dimensional nanostructured support 
based on the use of silicon nanopillars generated by etching was modified 
with an epithelial cell adhesion molecule antibody.169 The resulting 
device was shown to be highly efficient at capturing circulating cancer 
cells from whole blood samples.169 Applied to the quantification of these 
cells in patient samples, such systems can offer an additional diagnostic 
parameter in cancer management.169 Continued improvements in the 
design and reliability are expected to make it possible to combine such 
sensors with drug reservoirs and microfluidic technology to create 
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systems that can be directly actuated in vivo by the binding of 
biomarkers.  
 
Role of Nanobiotechnology in Personalized Medicine 
 
Personalized medicine simply means the prescription of specific 
therapeutics best suited for an individual. It is usually based on 
pharmacogenetics, pharmacogenomics and pharmacoproteomics, but 
other individual variations in patients are also taken into consideration.153 
Apart from refinements in molecular diagnostics, an important basis of 
personalized medicine, nanobiotechnology also helps in the discovery of 
biomarkers that are crucial for the development of personalized 
medicine. A good example of the application of nanobiotechnology for 
personalized medicine is that of cancer170: variation in the behavior of 
cancer of the same histological type from one patient to another is also 
taken into consideration. Personalization of cancer therapies is based on a 
better understanding of the disease at the molecular level and 
nanotechnology will play an important role in this area.153 
Applications of nanobiotechnology are beginning to show an impact on 
the practice of conventional medicine. Promoted by the National 
Institutes of Health of the United States, nanomedical research is 
providing easy access to innovative nanodevices and nanosystems based 
on the rational design and precise integration of functional nanomaterials 
for the further development of clinical nanomedicine.171 Nanotechnology 
will enable design and delivery of more effective drugs with targeted 
delivery increasing efficacy and reducing toxicity. Although considerable 
progress has been made in identifying the molecular components of the 
mitochondrial machinery, no effective treatment for diseases caused by 
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mitochondrial dysfunction have been developed. An impediment to 
manipulating mitochondria within living cells is their limited accessibility 
to direct physical, biochemical and pharmacological approaches. 
Advances in nanotechnology are providing new tools that have the 
potential for the diagnosis and therapy of mitochondrial disorders.172 
Nanotechnology provides the basis of computer-controlled molecular 
tools that are much smaller than a human cell and built with the accuracy 
and precision of drug molecules. Such tools will be used for interventions 
in a refined and controlled manner at the cellular and molecular levels.153 
They could remove obstructions in the circulatory system, kill cancer 
cells, or take over the function of subcellular organelles. Instead of 
transplanting artificial hearts, a surgeon of the future would be 
transplanting artificial mitochondria. Refinements in nanodiagnostics will 
enable routine detection of single particles of viruses or bacteria in 
minuscule samples. Nanotechnology will also provide devices to examine 
tissue in minute detail. Biosensors that are smaller than a cell would give 
us an inside look at cellular function. Tissues could be analyzed down to 
the molecular level, giving a completely detailed ‘snapshot’ of cellular, 
subcellular and molecular activities. Such a detailed diagnosis would 
guide the appropriate treatment. Although several nanomedicine-related 
applications of nanobiotechnology are in development or nearing 
commercialization, they face the usual regulatory approval hurdles 
encountered in the introduction of other innovative technologies and 
products. Judging from the progress and the increasing interest in this 
area during the past decade, further positive developments are predicted 
in nanomedicine in the next decade.153 For example, gold nanoparticles 
are used in high throughput genomic detection devices without the need 
for polymerase-chain-reaction (PCR) amplification but with a sensitivity 
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similar to that of PCR-based assays (see Fig. 8).173 This technology has 
been approved by the FDA for genetic screening to determine drug 
sensitivity and to detect genetic mutations but it is not still approved for 
employment in European countries. 
 
 
 
Figure 8 The Verigene System® Nanomaterials such as gold 
nanoparticles can be coated with biorecognition molecules to 
target either a patient’s DNA or a protein sample. Here, gold 
nanoparticles are coated with a complementary oligonucleotide 
(single-stranded DNA) that recognizes the variant gene 
sequence captured on a surface. Once nanoparticles are bound 
to the surface, the signal is amplified by means of a silver 
nitrate reduction reaction. This technique has been reported to 
have sensitivity equivalent to that of the polymerase-chain-
reaction assay for genetic analysis. 
 
  
 
 
 
 
 
 
 
 
 
Chapter II 
Aim of the research 
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Warfarin is the most widely prescribed oral anticoagulant in North 
America and Europe.174 Despite the availability of the international 
normalized ratio (INR), a laboratory test that is universally used to 
measure the anticoagulant effect of warfarin, serious adverse responses, 
including hemorrhagic and thromboembolic events, continue to 
complicate therapy, making warfarin one of the drugs most often 
responsible for emergency room visits.174 The relationship between the 
dose of warfarin prescribed and the individual response is regulated by 
genetic and environmental factors that can influence the absorption of 
warfarin, its pharmacokinetics, and pharmacodynamics. Since the Food 
and Drug Administration revised the label for warfarin to note the 
importance of VKORC1 and CYP2C9 polymorphisms,175 several groups 
have proposed genotype-guided maintenance dose algorithms that 
incorporate both genetics and demographic parameters, such as age, 
weight, and body surface area.73,176 
Selective Serotonin Reuptake Inhibitors (SSRIs) antidepressant 
drugs are the mainstay treatment for the depressive and anxiety 
disorders. A large number of studies report the association between the 5-
HTTLPR genetic polymorphism of the serotonin transporter and the 
different response to treatment with the antidepressant drugs belonging 
to the class of the SSRI. It is known that the antidepressant effect exert by 
the SSRIs is more effective and occurs more rapidly99,17784 in individuals 
homozygous for the L allele, which confers a high functional activity of 
the serotonin transporter.96,97,121 Furthermore, subjects who carrying at 
least on copy of the S allele, which confers a reduced functional activity of 
the serotonin transporter, are at increased risk of no remission of 
depressive symptoms when treated with SSRIs178,83 and they have a 
higher incidence of adverse effects following the treatment.179 
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Evidence-based medicine applies guidelines developed on the basis of 
consensus from randomized clinical trials (RCTs). These RCTs are usually 
performed in carefully selected patient-population studied under 
strongly regulated conditions. It often is a challenge to translate the 
results of the RCTs to a generic cohort of patients in the real world.180 
Since that considerations, the aims of this thesis were:  
 
 To provide evidence in a translational perspective of the feasibility 
of the application in the community care of pharmacogenetic tests 
for the routine use of oral anticoagulant therapy with warfarin and 
Selective Serotonin Reuptake Inhibitors (SSRI) antidepressant 
drugs in oncology and psychiatry;  
 To evaluate the genetic polymorphisms of CYP2C9 and VKORC1 
and to develop and evaluate algorithms based on these genetic 
information; 
 To evaluate the genetic polymorphism of the Serotonin Transporter 
(SERT) for the assessment of the SSRIs antidepressant response in 
oncology and psychiatry; 
 To assess the applicability in community care of the 
pharmacogenetic of oral anticoagulant and antidepressant drugs in 
the perspective of the development of nanotechnological devices. 
  
 
 
 
 
 
 
 
 
Chapter III 
Materials and methods 
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3.1 Protocols of the studies and patients recruitment 
 
The studies described were conducted in accordance with the 
principles laid down in the Helsinki Declaration and the International 
Guidance for Good Clinical Practice. Written informed consent was 
obtained from all subjects prior to study enrollment. The research 
protocols for the studies were approved by the Ethical Committee of the 
Azienda per i Servizi Sanitari n.1 Triestina (ASS1). 
 
 Warfarin 
 
The study was a retrospective and observational investigation 
including patients treated with warfarin who referred to the Centre for 
the Cardiovascular disease (CCV) and to the Distretto n.1 of the ASS1 of 
the National Health System.  
Inclusion criteria: 
 
 Subjects either male or female between the age of xx and yy; 
 INR stability, defined as 6 consecutive INR determination between 
the therapeutic range (+/- 0.2 INR units); 
 Subjects provide written informed consent. 
 
Exclusion criteria: 
 Subjects with an inadequate compliance to the oral anticoagulant 
therapy; 
 Period of treatment less than 1 month; 
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 Subjects do not provide written informed consent. 
 
Subjects who met the inclusion criteria provide a biological sample 
obtained from oral mucosa by means of standard brush. Finally, the 
study included 101 patients. 
 
 SSRIs antidepressant drugs  
 
Oncological patients 
 
The subjects initially included in this study were 46 consecutive 
patients, 25 men (54%) and 21 women (46%), who were admitted to the 
hospice of the Azienda per i Servizi Sanitari 6, S. Vito al Tagliamento 
(Pordenone, Italy). At admission and recruitment, all patients had a 
diagnosis of cancer and their tumors were located in the lung (9 patients), 
breast (6 patients), prostate (5 patients), colon (5 patients), ovary (4 
patients), pancreas (3 patients), brain (2 patients), kidney (2 patients), 
stomach (2 patients), biliary tract (1 patient), tongue (1 patient), 4 patients 
were leukemic and one tumor had an unreported origin. Eleven patients 
(61%) were treated with chemotherapy, 5 (27%) with radiotherapy, and 9 
(50%) with surgery; 15 patients (83%) had metastases. Each patient was 
carefully evaluated at admission by the palliative care team by means of 
the Hospital Anxiety and Depression Scale (HADS) and the Mini Mental 
Adjustment to Cancer (Mini-MAC) , and those who met the criteria for a 
depressive disorder according to DSM-IV and who were clinically judged 
to potentially benefit from antidepressant treatment were treated with 
escitalopram. Eighteen patients (10 men and 8 women) completed a 
period of 2 weeks’ treatment. 
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Psychiatric patients 
 
 The study was a retrospective, observational investigation 
including a sample of subjects who have been diagnosed a depressive 
mood disorder according to the criteria of the ICD-10 (International 
Classification of Diseases 10 - chapter V, F32 depressive episode or F33 
recurrent depressive disorder). Subjects were identified through the 
database of Siasi Web-DSM in collaboration with the Department of 
Mental Health (DSM) of the Azienda per i Servizi Sanitari No.1 
"Triestina" (ASS1) belonging to the National Health System. The database 
including socio-demographic and clinical characteristics of patients taken 
into care at the four Mental Health Centres (CSM) in Trieste.  
 
Inclusion criteria: 
 Subjects either male or female between the age of 20 and 85; 
 Subjects not previously taken into care by the DSM of ASS1; 
 Subjects who have received the first contact with the CSM of 
Maddalena or Via Gambini with an initial diagnosis of F32 and F33; 
 Subjects who received a prescription for an antidepressant drugs. 
 
Subjects were psychometrically evaluated by means of the 
Montgomery-Asberg Depression Rating Scale and a biological sample 
was obtained from oral mucosa by rubbing the buccal wall with a 
standard brush. Finally, 132 subjects have been identified, however the 
number was significantly reduced due to several factors such as death, 
change of residence address or the not expression of the consent for the 
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participation in the study. At the end, this study considered 43 patients 
recruited from October, 2010 to May, 2011. 
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3.2 Methods 
 
3.2.1 DNA extraction 
 
Biological samples were obtained from oral mucosa cells by means 
of standard brushes (MasterAmpTM buccal swab brushes, Epicentre 
Biotechnologies). Genomic DNA was isolated from the biological samples 
using a commercial kit (GenEluteTM Blood genomic DNA kit; Sigma-
Aldrich Co). Cells are lysed with a chaotropic salt-containing buffer to 
ensure denaturation of macromolecules. DNA is bound to the spin 
column membrane and the remaining lysate is removed by 
centrifugation. A filtration column is used to remove cell debris. After 
washing to remove contaminants, the DNA is eluted with buffer into a 
collection tube. The purified DNA was frozen at -20°C until the 
genotyping. 
 
3.2.2 Single Nucleotide Polymorphisms detection 
 
 Polymerase Chain Reaction (PCR) 
 
Genotyping of the allelic variations in the 5-HTTLPR has been 
carried out by standard polymerase chain reaction (PCR) amplification 
(see Fig. 9) using the primers described by Gelernter181, and with the GC-
rich PCR System (Roche Molecular Biomedicals) in a 50-µL reaction 
containing 20-100 ng of DNA, 100 µm deoxyribonucleoside triphosphate 
(dNTPs), 20 pmol for each primer, and 1.5 mM MgCl2. DNA was 
denatured at 95°C for 10 minutes and subjected to 40 cycles of 40 seconds 
of denaturation at 94°C, 45 seconds of annealing at 56°C, 40 seconds of 
extension at 72°C, and 10 minutes of final extension at 72°C. The PCR 
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amplification products were separated on a 2% agarose gel and 
visualized in ultraviolet light after Gel Red™ staining. 
 
 
Figure 9. Schematic overview of PCR cycles 
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 Real-Time PCR-TaqMan®  assay 
 
The discrimination of the allelic variants within the VKOC1 gene 
have been performed on an Applied Biosystems HT7900 real-time PCR 
(Applied Biosystems, Foster City, CA) with commercially available and 
validated Applied Biosystems TaqMan® SNP Genotyping Assays for 
VKORC1 –1639 G>A (rs9923231). TaqMan® probes consist of a 
fluorophore attached to the 5’-end of the oligonucleotide probe and a 
quencher at the 3’-end (see Fig. 10). 
 
 
Figure 10. Schematic overview of TaqMan® probe 
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The quencher molecule quenches the fluorescence emitted by the 
fluorophore when excited by the cycler’s light source. As long as the 
fluorophore and the quencher are in proximity, quenching inhibits any 
fluorescence signals (see Fig. 10). TaqMan® probes are designed such that 
they anneal within a DNA region amplified by a specific set of primers. 
As the Taq polymerase extends the primer and synthesizes the nascent 
strand, the 5' to 3' exonuclease activity of the polymerase degrades the 
probe that has annealed to the template. Degradation of the probe 
releases the fluorophore from it and breaks the close proximity to the 
quencher, thus relieving the quenching effect and allowing fluorescence 
of the fluorophore. Hence, fluorescence detected in the real-time PCR 
thermal cycler is directly proportional to the fluorophore released and the 
amount of DNA template present in the PCR. 
 
 Pyrosequencing  
 
Genotyping of CYP2C9 *2 and *3 alleles was performed by PCR 
followed by a pyrosequencing analysis of the amplified DNA. 
Pyrosequencing technique is usually suited for sequencing of shorter 
fragments as compared to the Sanger sequencing method. The principle 
(see Fig. 11) is based on the extension of single nucleotides using the 
polymerase reaction and the release of pyrophosphate (PPi).  
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Figure 11. Overview of principle of pyrosequencing analysis 
 
 
In brief, a sequencing primer is annealed to a single-strand PCR fragment 
and deoxynucleotide triphosphates (dNTPs) are added in a user 
predefined order. If the nucleotide is complementary to the base on the 
DNA strand, the released PPi is converted to ATP by ATP-sulfurylase in 
the presence of adenosine 5’ phosphosulfate (APS). The ATP generated 
will be used by luciferase to convert luciferin to oxyluciferin during 
which light is produced. The light created in the reaction is proportional 
to the amount of incorporated nucleotide and detected by a charge 
coupled device (CCD) camera. Unincorporated dNTPs and ATP are 
degraded between each cycle by apyrase. The result is displayed in a 
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pyrogram and the height of each peak is used for the determination of the 
sequence (see Fig. 11). 
 
3.3 Statystical analysis 
 
The analysis of the clinical, socio-demographic and psychometric 
characteristics was conducted by means of the use of SPSS software 
version 15.0 (SPSS Inc., Chicago, IL, USA). Results are presented as 
mean±SEM unless stated otherwise. A p value of less than 0.05 was taken 
as statistically significant. 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter IV 
Results and discussion 
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4.1 Pharmacogenetic of warfarin 
 
4.1.1 Clinical, demographic and genetics characteristics of the 
patients 
 
The first part of this study was focused on the enrolment of the 
patients from the Center for cardiovascolar disease (CCV) and the 
distretto 1 both of the Azienda per i Servizi Sanitari n.1 Triestina of the 
National Health System. 
101 patients who met the criteria have been identified for the inclusion in 
the study. Their demographic and clinical characteristics are summarized 
in Table 5. Out of the 101 subjects included, 56 (55.4%) were male and 45 
(44.6%) female with a mean age of 69.55±0.98. The main indications for 
anticoagulation with warfarin were atrial fibrillation or flutter (78.4%), 
cardiac valve replacement (16.7%), pulmonary embolism (2.9%) and deep 
vein thrombosis (2.0%). The mean dose administered was 28.77±1.47 
mg/wk. Genotyping has been conducted in order to identify the allelic 
variants of the gene coding CYP2C9 and VKORC1. The allelic frequencies 
of CYP2C9 and VKORC1 are reported in the table 5. The observed 
genotype frequencies showed no deviation from Hardy-Weinberg 
equilibrium.  
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4.1.2 Association between CYP2C9 and VKORC1 allelic variants 
and warfarin dose 
 
In order to identify the role of genetic in the variability of warfarin, 
the dose required was analyzed in relation to the allelic variants of each 
gene considered. The mean warfarin weakly dose requirement was 
36.86±3.46 mg in patients with the VKORC1 (-1639) GG genotype, which 
was signiﬁcantly higher (p= .000) than that in the GA (26.96±1.44 mg) and 
AA (19.58±2.21 mg) genotype patients. The results extend the known 
association between CYP2C9 genotype and warfarin dose. There were 
significant differences in mean dose requirements between each of the 
variant alleles compared with the wild type. The mean warfarin weakly 
dose requirement was 32.82±2.20 mg/wk in CYP2C9 homozygous wild-
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type patients, which was signiﬁcantly higher (p= .005) than that in *1/*2 
(28.69±2.22 mg), *1/*3 (25.16±3.52 mg), *2/*2 (43.75±27.5 mg), and *2/*3 
patients (13.40±2.42 mg). Distributions of dose within the different 
genotypes are illustrated in Table 6 and 7. The data were analyzed by 
means of the parametric test Analysis of the Variace (ANOVA). 
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Moreover, combined effect of both VKORC1 and CYP2C9 variants on the 
dose has been examined. Table 8 and Figure 12 reported the distribution 
of warfarin dose among the possible combination of genotypes. Among 
variants, the highest dose is required by patients carrying the wild-type 
alleles both for VKORC1 and CYP2C9. 
 
 
 
Figure 12.Distribution of the warfarin dose in 
relation to VKORC1 and CYP2C9 
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4.1.3 Association between clinical and genetic data with warfarin 
dose 
 
An ordinary stepwise linear regression method incorporates both 
genetic and clinical data was used to develop a pharmacogenetic 
algorithm for the prediction of warfarin dose. The best regression dose 
model is reported in the Table 9. As reported in the table, the multivariate 
regression model including the variables weight, smoking habits, 
VKORC1 and CYP2C9 genotype produced the best model for estimating 
warfarin dose, having the largest R2 value (0.50). Among clinical 
characteristics, smoking habits appears to be the major determinants of 
the dose required by patients. 
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4.2 Pharmacogenetic of SSRIs 
 
Oncological patients.  
 
4.2.1 Clinical, demographic and genetics characteristics of the 
patients 
 
Eighteen patients (10 men an were admitted to the hospice of the 
Azienda per i Servizi Sanitari 6, S. Vito al Tagliamento (Pordenone, Italy) 
and completed a period of 2 weeks’ treatment; their demographic, clinical 
and genetic characteristics are reported in the table 10. Out of the 18 
patients, 10 were male (55.6%) and 8 female (44.4%) with a mean age of 
71.6±2.01. At admission and recruitment, all patients had a diagnosis of 
cancer and their tumors were located in the lung (2 patients), breast (4 
patients), prostate (2 patients), colon (2 patients), ovary (2 patients), brain 
(2 patients), kidney (2 patients), tongue (1 patient), and one tumor had an 
unreported origin. Eleven patients (61%) were treated with 
chemotherapy, 5 (27%) with radiotherapy, and 10 (55.6%) with surgery; 
15 patients (83%) had metastases. Out of the 18 patients considered, 11 
(61%) were found to carry at least one “s” allele, and 7 (39%) were 
homozygous for the “l/l” alleles. 
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4.2.2 Association between response to treatment with escitalopram 
and 5-HTTLPR allelic variants 
 
After 2 weeks of treatment with escitalopram, a significant 
reduction was observed in anxiety scores of HADS and in anxious 
preoccupation and hopelessness-helplessness scores of the Mini-MAC 
(Table 11). The data were analyzed by means of the non-parametric test of 
Wilcoxon. 
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When the 5-HTTLPR polymorphism was considered, HADS 
anxiety scores were significantly decreased only in patients carrying the 
“s/s” and “s/l” variants, whereas those with “l/l” genotypes displayed a 
significant reduction of Mini-MAC anxious preoccupation (Table 12); no 
significant difference was found for the remaining subscales. The data 
were analyzed by means of the non-parametric test of Wilcoxon. 
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Psychiatric patients 
 
4.2.3 Clinical, demographic and genetics characteristics of the 
patients 
 
Table 13 summarizes the demographic and clinical characteristics 
of the 43 subjects included in the study. The statistical analysis found no 
significant differences between subjects in relation to the two CSM (chi-
square test). Subjects were aged between 20 and 85 years, with an mean 
age of 57.40±2.00. Out of the 34 subjects enrolled by the CSM of Via 
Gambini, 19 (55.9%) had received a diagnosis of depressive episode (F32) 
and 15 (44.1%) of recurrent depressive disorder (F33). Moreover, 15 
(44.1%) were aged between 20 and 55 and 19 (55.9%) between 56 and 85 
years. 26 patients (76.5%) were females and 8 (23.5%) were male. About 
the subjects identified by the CSM of Maddalena, 4 patients (44.4%) had 
received a diagnosis of F32 and 5 (55.6%) F33. Three subjects aged 
between 20 and 55 years (33.3%) and 6 (66.7%) aged between 56 and 85 
years. Moreover, 8 (88.9%) were females, and only 1 (11.1%) was male.  
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The allelic frequencies of 5-HTTLPR are reported in the table 14. The 
observed genotype frequencies showed no deviation from Hardy-
Weinberg equilibrium (Chi-square=0.22, df=1, p=0.636). 32 patients were 
carriers of at least one copy of the “s” allele, and 11 subjects were 
homozygous for the “l” allele. 
 
 
aFunctional activity classified as indicated by Lesh and 
colleagues94 
 
Moreover, allelic variants were analyzed also in relation to initial 
diagnosis. No significant differences have been observed in the 
distribution of 5-HTTLPR genotypes among diagnosis (Chi-square=0.612, 
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df=1, p=434). The distribution of the allelic variants are reported in the 
table 15. 
 
 
 
Out of 23 patients who have received a diagnosis of depressive episode 
(F32), 16 (69.6%) carried at least one copy of the “s” allele, whereas 7 
(30.4%) were homozygous for the “l” allele. Considering the subjects who 
were diagnosed with a recurrent depressive disorder (F33), out of the 20 
considered, 16 (80.0%) were carriers of low functional activities variants 
of 5-HTTLPR (S/S or S/L) and 4 (20.0%) were homozygous for the “l” 
allele. 
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4.2.4 Association between 5-HTTLPR allelic variants and 
depression 
 
To assess the influence of 5-HTTLPR on the severity of the 
depression, the scores of MADRS scale were analyzed in relation to allelic 
variants of the SERT. The data were analyzed by means of the non-
parametric test of Mann-Whitney.  
 
 
 
The results (Table 16) show that subjects with genotype S/S and S/L have 
higher scores, with a slightly significant difference than those who are 
homozygous for the “l” allele (18.08±2.12 vs 12:00±2.54, p=0.098). Such 
difference indicates a greater severity of depressive disorder for patients 
who carrying at least one copy of the “s” allele. 
 
  
 
 
 
 
 
 
 
 
 
Chapter V 
Conclusions 
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5.1 Pharmacogenetic of warfarin 
 
Warfarin therapy, particularly during the initiation period, is 
associated with a high incidence of overanticoagulation with resultant 
bleeding, as the inability to take into account interindividual and 
intraindividual variability in response to the drug makes accurate dose 
predication impossible. This is frequently a cause for concern. It has been 
estimated that almost half of patients with atrial fibrillation who are 
eligible for, and would beneﬁt from, warfarin therapy are not receiving 
the drug because of the associated risks and monitoring costs. In this 
point of view, the contribution of CYP2C9, VKORC1 and other clinical 
and demographic factors has been investigated in patients in the contest 
of the community medicine. The analysis of the dose of warfarin in 
relation to each genetic factors confirmed that there were signiﬁcant 
differences in mean dose requirements between each of the variant alleles 
compared with the wild type both for CYP2C9 and VKORC1 also in a 
cohort of patients from the community medicine. Moreover, this has been 
confirmed also when genetic, clinical and demographic factors have been 
analyzed in order to define the major determinant of warfarin dose and to 
identify an algorithm for the prediction of the dose. The results indicate 
the role in the determination of the warfarin dose of the allelic variants 
considered jointly with the weight of patients and their smoking status. 
These results appear to support the need of the pharmacogenetic 
characterization of the patients at the initiation of the warfarin therapy 
also in the general practice and in community medicine. 
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5.2 Pharmacogenetic of SSRIs 
 
Oncological patients 
 
Depressive mood disorders show an increasing incidence and 
prevalence in the general population and are extensively treated with 
antidepressants, in particular SSRIs. Difficulties in the mental adaptation 
to cancer are common in patients with advanced disease and may 
significantly and negatively affect quality of life; studies on the effects of 
treatment with SSRI antidepressants in these patients are scarce. In the 
present study, treatment with escitalopram significantly attenuated 
anxiety as identified using HADS and improved the mental adaptation to 
cancer by reducing anxious preoccupation and hopelessness-helplessness 
as determined with Mini-MAC. The results obtained also indicate that the 
effects of escitalopram on anxiety and anxious preoccupation depended 
on 5-HTTLPR genetic polymorphism. In fact, anxiety was significantly 
and markedly reduced only in carriers of at least one “s” allele, whereas a 
significant and marked reduction of anxious preoccupation occurred only 
in homozygotes for the “l” allele. The characterization of the patients’ 
genetic polymorphism of the serotonin transporter 5-HTTLPR thus 
appears to contribute significantly to the therapeutic response to SSRIs, 
indicating that pharmacogenetics can be usefully integrated in the 
palliative care for the treatment of mood disorders and difficulties in the 
mental adaptation to cancer in patients with advanced disease.  
 
 
C h a p t e r  V - C o n c l u s i o n s | 75 
 
Psychiatric patients 
 
Response to antidepressant therapy is often incomplete with 
approximately 30–40% not responding at all to the first antidepressant 
given and about 60–70% not achieving remission. Moreover, 
antidepressant treatment is characterized by a delayed time of onset of 
the clinical improvement and by a variety of adverse effects. Recent 
literature shown that in subjects with difficulties to adaptation to stressful 
life events, the development of depressive symptoms are related to the 
polymorphism in the gene coding for the serotonin transporter (SERT) 
with a specific Gene x Environment interaction.  
In this study, the response to antidepressant treatment was analyzed in 
relation to the allelic variants of 5-HTTLPR genetic polymorphism of 
SERT. 43 subjects suffering from depressive disorders and previously 
treated with an antidepressant were genotyped for 5-HTTLPR and 
psychological evaluated by Montgomery-Asberg Depression Rating Scale 
(MADRS) to detect the severity of depression. The results indicate that 
the incidence of depressive mood disorder is greater in subjects carrying 
at least on copy of the “s” allele (S/L and S/S) and these patients have 
higher scores, with a marginally significant difference, compared to those 
who are homozygous for “l” allele. 
The data obtained appear to be of interest because they refer to mental 
distress and its treatment in the field of community medicine, which is 
poorly represented in the literature. Moreover, these results seem to 
encourage future research aiming to consider a larger sample, in the 
perspective of a personalized intervention in the clinical practice of mood 
disorders. 
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General conclusions 
 
 The results obtained for the warfarin pharmacogenetic in 
community care are in general agreement with those reported by 
the majority of the trials, which are performed in carefully selected 
patient population studied under strongly controlled conditions, 
and support the inclusion of genetic data in the algorithms used for 
choosing the initial dose of warfarin;  
 
 The pharmacogenetic test of 5-HTTLPR has been evaluated in 
community care on oncological patients with advanced cancer and 
in psychiatric patients treated with antidepressants; 5-HTTLPR 
appears to be predictive of the response to treatment with SSRIs 
also in the community care; 
 
 The pharmacoeconomic profile of these pharmacogenetic 
approaches appear to be favorable, for the limited cost of these tests 
in relation to the benefit reached with the optimization of the 
response and with the reduction of the adverse effects; 
 
 These conclusions are in favor of the development of 
nanotechnological devices useful for the implementation of 
pharmacogenetic tests in general practice and community care. 
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